Vivus' $110m 'band-aid' could cost $147.1m
This article was originally published in Scrip
Executive Summary
Vivus is leveraging sales from the weight loss drug Qsymia (phentermine and topiramate) that it has not yet been able to achieve in order to borrow up to $110 million that will finance its commercial programs and other unspecified expenses.